Skip to search formSkip to main contentSkip to account menu

LY2605541

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
The impact of the novel basal insulin LY2605541 (LY) on hepatic and nonhepatic glucose uptake (non-HGU) was evaluated. Conscious… 
Highly Cited
2014
Highly Cited
2014
To assess the pharmacokinetics (PK) and glucodynamics (GD) of LY2605541 in patients with type 2 diabetes mellitus. 
Highly Cited
2014
Highly Cited
2014
LY2605541 is a novel basal insulin analog with a prolonged duration of action. Two Phase I studies assessed LY2605541… 
Review
2014
Review
2014
There is a clinical rationale for a basal insulin with a predictable action and low inter‐ and intra‐individual variability… 
Review
2014
Review
2014
Insulin remains the most effective and consistent means of controlling blood glucose levels in diabetes. Since 1946, neutral… 
2014
2014
OBJECTIVE To use continuous glucose monitoring (CGM) to evaluate the impact of the novel, long-acting basal insulin analog… 
Highly Cited
2013
Highly Cited
2013
OBJECTIVE To compare effects of LY2605541 versus insulin glargine on daily mean blood glucose as part of a basal-bolus regimen… 
Review
2013
Review
2013
Elderly patients with type 2 diabetes mellitus (T2DM) are a rapidly emerging population that presents unique clinical challenges… 
Highly Cited
2012
Highly Cited
2012
OBJECTIVE To evaluate whether LY2605541 results in lower fasting blood glucose (FBG) versus insulin glargine (GL). RESEARCH… 
Highly Cited
2012
Highly Cited
2012
IN BRIEF Biosimilar insulins are likely to enter the insulin landscape as patents for major branded insulin products start to…